What question did this study set out to answer?

To examine the relationship of TERT promoter mutations and BRAF V600E with clinicopathological features and tumor aggressiveness in papillary thyroid carcinoma.

March 1, 2016OncotargetOpen Access

BRAFandTERTpromoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients

View Full Paper

Ask AI

Bookmark

Authors

LJLangping JinResearch Experiences for Undergraduates ECEndong ChenWenzhou Medical University SDSiyang DongWenzhou Medical University

Discussion

Member takes

Overview

Observational study reveals cooperative BRAF and TERT promoter mutations heighten aggressiveness in papillary thyroid cancer, indicating dual testing improves risk stratification.

Key Points

To examine the relationship of TERT promoter mutations and BRAF V600E with clinicopathological features and tumor aggressiveness in papillary thyroid carcinoma.
Extracted genomic DNA from primary papillary thyroid cancer tumors in N=653 patients.
Performed Sanger sequencing to identify BRAF V600E and TERT promoter mutations, correlating detected genotypes with clinicopathological features.
BRAF V600E was identified in 63.7% (416/653) and TERT promoter mutations in 4.1% (27/653) of patients, with TERT mutation prevalence reaching 9.8% in tumors ≥ 1.5 cm and occurring more frequently in BRAF-positive than wild-type tumors (5.3% vs 2.1%, P=0.050).
Both BRAF V600E and TERT promoter mutations independently associated with advanced patient age, larger tumor size, capsular invasion, extrathyroidal invasion, and advanced disease stages.
Co-occurrence of BRAF V600E and TERT promoter mutations showed a cooperative association with aggressive features, exhibiting extrathyroidal invasion in 54.5% (12/22) of dual-mutation cases compared to 9.9% (23/232) lacking both mutations (P < 0.001).

Cite This Study

Jin et al. (2016) studied this question.

synapsesocial.com/papers/69dd67987dbdc4ad1440c8b0 https://doi.org/10.18632/oncotarget.7811

View Full Paper

Ask AI

Bookmark

March 1, 2016OncotargetOpen Access

BRAFandTERTpromoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients

View Full Paper

Ask AI

Bookmark

Authors

LJLangping JinResearch Experiences for Undergraduates ECEndong ChenWenzhou Medical University SDSiyang DongWenzhou Medical University

Discussion

Member takes

Overview

Observational study reveals cooperative BRAF and TERT promoter mutations heighten aggressiveness in papillary thyroid cancer, indicating dual testing improves risk stratification.

Key Points

To examine the relationship of TERT promoter mutations and BRAF V600E with clinicopathological features and tumor aggressiveness in papillary thyroid carcinoma.
Extracted genomic DNA from primary papillary thyroid cancer tumors in N=653 patients.
Performed Sanger sequencing to identify BRAF V600E and TERT promoter mutations, correlating detected genotypes with clinicopathological features.
BRAF V600E was identified in 63.7% (416/653) and TERT promoter mutations in 4.1% (27/653) of patients, with TERT mutation prevalence reaching 9.8% in tumors ≥ 1.5 cm and occurring more frequently in BRAF-positive than wild-type tumors (5.3% vs 2.1%, P=0.050).
Both BRAF V600E and TERT promoter mutations independently associated with advanced patient age, larger tumor size, capsular invasion, extrathyroidal invasion, and advanced disease stages.
Co-occurrence of BRAF V600E and TERT promoter mutations showed a cooperative association with aggressive features, exhibiting extrathyroidal invasion in 54.5% (12/22) of dual-mutation cases compared to 9.9% (23/232) lacking both mutations (P < 0.001).

Cite This Study

Jin et al. (2016) studied this question.

synapsesocial.com/papers/69dd67987dbdc4ad1440c8b0 https://doi.org/10.18632/oncotarget.7811

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark